The engagement of NKG2D with its ligands expressed on tumor cells likely facilitates tumor killing by Cbx3/HP1γ-deficient CD8+ effector T cells through the enhanced production of PRF1, GrB and INF-γ. This evidence concerns the gene CD8A and neoplasm.